

Reply

Resposta

Lineu Cesar WERNECK¹, Paulo José LORENZONI¹, Renata Dal-Prá DUCCI¹,
Otto Hernández FUSTES¹, Cláudia Suemi Kamoi KAY¹, Rosana Herminia SCOLA¹

We thank Dr. Josef Finsterer for his comments that completed our paper¹.






The scope of the paper was to present a review of pharmacological therapy of Duchenne muscular dystrophy (DMD). We agree that the points raised by Dr. Finsterer are very important, as we point out in the conclusion of the

paper. Due to policies of the *Arquivos de Neuropsiquiatria*, the paper was in the limit of words and references for review articles. For this reason, it was not possible to extend the discussion about investigation and treatment of other aspects of DMD as he has pointed out and as it is performed in our center^{2,3}.

References

1. Werneck LC, Lorenzoni PJ, Ducci RD, Fustes OH, Kay CSK, Scola RH. Duchenne muscular dystrophy: an historical treatment review. *Arq Neuropsiquiatr*. 2019 Sep;77(8):579-89. <https://doi.org/10.1590/0004-282X20190088>
2. Cirino RHD, Scola RH, Ducci RD, Wermelinger ACC, Kay CSK, Lorenzoni PJ, et al. Predictors of early left ventricular systolic dysfunction in Duchenne muscular dystrophy. *Muscle Nerve*. 2018 Jul;58(1):84-9. <https://doi.org/10.1002/mus.26102>
3. Cirino RHD, Scola RH, Ducci RD, Camarozano AC, Kay CSK, Lorenzoni PJ, et al. Evaluation of left-sided heart chambers with novel echocardiographic techniques in men with Duchenne and Becker muscular dystrophy. *Am J Cardiol*. 2019 Mar;123(6):972-8. <https://doi.org/10.1016/j.amjcard.2018.12.011>

¹Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.

Lineu Cesar WERNECK  <https://orcid.org/0000-0003-1921-1038>; Paulo José LORENZONI  <https://orcid.org/0000-0002-4457-7771>;
Renata Dal-Prá DUCCI  <https://orcid.org/0000-0002-1673-5074>; Otto Hernández FUSTES  <https://orcid.org/0000-0003-0778-5376>;
Cláudia Suemi Kamoi KAY  <https://orcid.org/0000-0003-0173-0809>; Rosana Herminia SCOLA  <https://orcid.org/0000-0002-3957-5317>

Correspondence: Lineu Cesar Werneck; E-mail: lineu.werneck@hc.ufpr.br

Conflict of interest: There is no conflict of interest to declare.

Received on March 24, 2020; Accepted on March 25, 2020.

